Verastem Inc (VSTM) Stock Price, Quote & News

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 292 4200

Website: www.verastem.com

Address:

117 Kendrick Street, Suite 500, Needham, United States

HubAllianceModern Mar. 21 at 6:35 PM

$VSTM biotech, just watching.

0 · Reply

hermitkatt Mar. 20 at 8:05 PM

$VSTM triple witching, not bad. good weekend alll

0 · Reply

sweddle Mar. 20 at 7:51 PM

$VSTM

1 · Reply

sweddle Mar. 20 at 7:50 PM

$VSTM it’s almost like the entire market is on fire or something. Call me crazy but I think maybe there’s a global war going on and significant macro disruptions to include a popping private credit bubble. Na that’s crazy talk it’s just VSTM.

1 · Reply

Stoltz13 Mar. 20 at 7:47 PM

$VSTM I hate this current economy. It's like we're intentionally being f*cked.

0 · Reply

SagehenNed Mar. 20 at 7:20 PM

$VSTM Classic VSTM, tanking into the close and giving everything back from yesterday and more.

0 · Reply

GeniusLoci Mar. 20 at 3:09 PM

$VSTM Signals from the previous session: Bullish Engulfing + Stochastic Buy Signal + MACD Bullish Signal Line Cross + Pocket Pivot

0 · Reply

Csab6362 Mar. 20 at 1:02 PM

$VSTM Time to turn this game around! Huge value here…

0 · Reply

Alt_Fuel Mar. 20 at 10:58 AM

$VSTM GenFleet Massive Volume today March 20, 2026

0 · Reply

Sigmanomics Mar. 20 at 6:01 AM

Stocks sold off and short-term Treasury yields rose after oil surged beyond $113 a barrel as attacks on Middle East energy infrastructure intensified - https://sigmanomics.com/stream $VSTM $PL $GLD $QQQ

0 · Reply

Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play

Mar 17, 2026, 6:03 PM EDT - 4 days ago

Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

Mar 17, 2026, 4:44 PM EDT - 4 days ago

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers

Mar 4, 2026, 6:32 PM EST - 16 days ago

Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript

Mar 4, 2026, 4:01 PM EST - 17 days ago

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Feb 18, 2026, 7:30 AM EST - 4 weeks ago

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Feb 4, 2026, 7:30 AM EST - 6 weeks ago

Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

Jan 12, 2026, 4:01 PM EST - 2 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 30, 2025, 3:37 PM EST - 2 months ago

Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC

Dec 29, 2025, 4:01 PM EST - 2 months ago

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Dec 15, 2025, 4:01 PM EST - 3 months ago

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

Nov 25, 2025, 7:30 AM EST - 4 months ago

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Nov 14, 2025, 12:41 AM EST - 4 months ago

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 13, 2025, 4:07 PM EST - 4 months ago

Verastem Oncology Announces Proposed Public Offering of Common Stock

Nov 5, 2025, 7:30 AM EST - 4 months ago

Verastem Oncology to Present at Upcoming Investor Conferences

Nov 4, 2025, 10:16 AM EST - 4 months ago

Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:30 AM EST - 4 months ago

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Oct 23, 2025, 4:01 PM EDT - 5 months ago

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Oct 23, 2025, 7:30 AM EDT - 5 months ago

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 19, 2025, 4:15 AM EDT - 5 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Aug 13, 2025, 4:29 PM EDT - 7 months ago

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Aug 8, 2025, 8:55 PM EDT - 8 months ago

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 8 months ago

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Jul 29, 2025, 7:30 AM EDT - 8 months ago

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 24, 2025, 7:30 AM EDT - 8 months ago

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Jul 16, 2025, 8:22 AM EDT - 8 months ago

Verastem: The Market Is Ignoring The Progress

Jul 11, 2025, 4:12 PM EDT - 9 months ago

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Jun 30, 2025, 4:02 PM EDT - 9 months ago

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Jun 26, 2025, 11:16 AM EDT - 9 months ago

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Jun 24, 2025, 4:02 PM EDT - 9 months ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 2, 2025, 9:40 AM EDT - 10 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

May 28, 2025, 7:30 AM EDT - 10 months ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 5:01 PM EDT - 10 months ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 20, 2025, 8:30 AM EDT - 10 months ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

May 13, 2025, 4:34 PM EDT - 11 months ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 8, 2025, 1:17 PM EDT - 11 months ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 12:23 PM EDT - 11 months ago

U.S. FDA approves Verastem's cancer therapy

Apr 25, 2025, 9:00 AM EDT - 11 months ago

Verastem Oncology Announces $75 million Private Placement

Apr 23, 2025, 4:05 PM EDT - 11 months ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Apr 10, 2025, 2:35 PM EDT - 1 year ago

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Mar 25, 2025, 4:35 PM EDT - 1 year ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Feb 20, 2025, 4:05 PM EST - 1 year ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Jan 29, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 15, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 14, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 13, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Jan 3, 2025, 11:56 AM EST - 1 year ago

Verastem: Planning The PDUFA Run-Up

Jan 2, 2025, 11:39 AM EST - 1 year ago

Verastem: BLA Acceptance Puts Key Goals In Sight

HubAllianceModern Mar. 21 at 6:35 PM

$VSTM biotech, just watching.

0 · Reply

hermitkatt Mar. 20 at 8:05 PM

$VSTM triple witching, not bad. good weekend alll

0 · Reply

sweddle Mar. 20 at 7:51 PM

$VSTM

1 · Reply

sweddle Mar. 20 at 7:50 PM

1 · Reply

Stoltz13 Mar. 20 at 7:47 PM

$VSTM I hate this current economy. It's like we're intentionally being f*cked.

0 · Reply

SagehenNed Mar. 20 at 7:20 PM

$VSTM Classic VSTM, tanking into the close and giving everything back from yesterday and more.

0 · Reply

GeniusLoci Mar. 20 at 3:09 PM

$VSTM Signals from the previous session: Bullish Engulfing + Stochastic Buy Signal + MACD Bullish Signal Line Cross + Pocket Pivot

0 · Reply

Csab6362 Mar. 20 at 1:02 PM

$VSTM Time to turn this game around! Huge value here…

0 · Reply

Alt_Fuel Mar. 20 at 10:58 AM

$VSTM GenFleet Massive Volume today March 20, 2026

0 · Reply

Sigmanomics Mar. 20 at 6:01 AM

0 · Reply

Alt_Fuel Mar. 20 at 5:43 AM

$VSTM GenFleet ... https://www.cnbc.com/quotes/2595-HK

0 · Reply

Alt_Fuel Mar. 20 at 5:28 AM

$VSTM GenFleet ...

0 · Reply

Alt_Fuel Mar. 20 at 5:24 AM

$VSTM well ... LOOK at THAT ! GenFleet $29.78 UP + $3.78 ( +14.54%) https://www.investing.com/equities/genfleet-therapeutics

0 · Reply

bobbybottleserviz Mar. 20 at 2:24 AM

$VSTM were under lock and key.. we go where they want us to.. no news can help this stock even curing cancer

1 · Reply

Universaal Mar. 19 at 11:00 PM

$VSTM please reshare this , so fuools who blocked me they can also see

0 · Reply

Universaal Mar. 19 at 8:27 PM

$VSTM

1 · Reply

sweddle Mar. 19 at 6:31 PM

$VSTM

2 · Reply

Stoltz13 Mar. 19 at 6:27 PM

$VSTM one of my bright spots today. The market is burning down and we're going up...

0 · Reply

Marketismanipulated2 Mar. 19 at 1:37 PM

$VSTM wish i never bought ANY of this back. Luckily i only bought 1/3 back. Criminal

0 · Reply

Marketismanipulated2 Mar. 19 at 12:31 PM

$VSTM SURELY thos has hit bottom! Love all the fucking 16-18 dollar anaylyst upgrades as it keeps tanking. What a GD joke.

1 · Reply

Robertbuote Mar. 18 at 6:55 PM

$VSTM Company has been VERY clear they plan to focus limited resources on (1) developing 7375 in all its various incarnations, (2) completing 301 confirmatory trial (without exaggeration, upon which the short/medium term survival of the company depends (i.e. revenue), (3) and maybe continuing with Ramp 205. Everything else is noise, no matter how promising in preclinic. Maybe investigator sponsored trials can pick up the slack, but VSTM is laser focused on 7375 as their home run. That will take a lot of $$$. No room for nice to haves.

0 · Reply

Sdcharger Mar. 18 at 6:29 PM

$VSTM Nothing the company seems to do makes any difference. We’ve been on a one-way slide down for the past four months.

0 · Reply

Market Cap	488.36M
Revenue (ttm)	30.91M
Net Income (ttm)	-209.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-677.68%
Debt to Equity Ratio	1.33

Volume	3,828,400
Avg Vol	1,809,038
Day's Range	N/A - N/A
Shares Out	87.84M
Stochastic %K	17%
Beta	0.40
Analysts	Strong Sell
Price Target	$16.88